Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 680,800 shares, an increase of 300.2% from the December 15th total of 170,100 shares. Based on an average trading volume of 348,300 shares, the short-interest ratio is currently 2.0 days. Approximately 1.0% of the shares of the company are short sold.
Tiziana Life Sciences Stock Down 10.2 %
NASDAQ TLSA traded down $0.09 during trading hours on Monday, hitting $0.75. The company had a trading volume of 395,438 shares, compared to its average volume of 486,784. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74. The firm has a 50 day simple moving average of $0.88 and a 200 day simple moving average of $0.95.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC boosted its holdings in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 24.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 69,387 shares of the company's stock after buying an additional 13,500 shares during the period. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 as of its most recent SEC filing.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
